Lupin Enters Strategic Licensing Agreement for YUVEZZI™ to Commercialize Presbyopia Treatment in European Markets

Lupin Enters Strategic Licensing Agreement for YUVEZZI™ to Commercialize Presbyopia Treatment in European Markets​

Lupin Limited, a global pharmaceutical leader, has achieved a significant milestone in its specialty care expansion by partnering to commercialize YUVEZZI™, an ophthalmic product indicated for the treatment of presbyopia. VISUfarma B.V., a wholly owned subsidiary of Lupin, signed an Exclusive License Agreement with Visus Therapeutics, Inc., giving the rights to market and sell the drug across specific European territories.

The agreement grants Visus Therapeutics exclusive rights to manage regulatory activities, commercialization, marketing, promotion, distribution, and sale of YUVEZZI™ (a carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%) in the Licensed Territories: the European Union, the United Kingdom, Switzerland, Norway, and Iceland.

YUVEZZI™, which is described as a proprietary once-daily dual-agent eye drop, is designed to treat presbyopia, a condition characterized by the gradual loss of near vision acuity that typically begins around age 45.

The business scope of the agreement encompasses exclusive rights across these territories. The initial term of the contract extends until the twentieth anniversary of the first commercial sale in the respective country and includes potential renewal periods set at five years each, determined solely by VISUfarma's discretion.

Financial Details of the Exclusive Licensing Agreement​

The partnership involves a substantial commitment from Lupin’s subsidiary to secure market presence for YUVEZZI™. The total potential consideration under the agreement is structured as follows:

Strategic Benefit and Market Opportunity​

The collaboration is positioned to substantially strengthen Lupin’s ophthalmology portfolio and expand its Specialty Business presence across key European markets. This partnership provides long-term growth opportunities within the presbyopia treatment market.

Vinita Gupta, Chief Executive Officer of Lupin, stated that the agreement demonstrates a commitment to advancing specialty care. She highlighted that the partnership "further strengthens our vision care franchise and expands our presence across key European markets," underscoring Lupin's dedication to broadening access to differentiated therapies.

Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, noted that the collaboration with Lupin’s strong commercial operations in Europe is beneficial for making YUVEZZI™ available to millions of patients with presbyopia globally.

The transaction was confirmed not to fall within related party transactions, and none of the promoter or group companies hold an interest in this arrangement. Visus Therapeutics, a key entity in this deal, is described as a biopharmaceutical company affiliated with Tenpoint Therapeutics Holding Limited.

LUPIN Stock Price Movement​

As of 11:55 AM, shares of Lupin Limited are slipping by 0.28% in live trading, currently holding at ₹2218.7. The pharmaceutical stock has traded 215,276 shares so far this morning, reflecting a modest intraday pullback.